FULC — Fulcrum Therapeutics Share News
0.000.00%
Last trade - 00:00- $280.77m
- -$38.07m
Brief: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Fulcrum Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Fulcrum Therapeutics Q1 Basic EPS USD -0.28
Fulcrum Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Fulcrum Therapeutics Inc Myokardia Terminates Collaboration And License Agreement With Co
Fulcrum Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Fulcrum Therapeutics Sanofi To Terminate Collaboration And License Agreement With Fulcrum
Fulcrum Therapeutics Inc reports results for the quarter - Earnings Summary
Brief: Fulcrum Therapeutics Announces Recent Business Highlights And Financial Results For Q3 2024
Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.35
Fulcrum Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say (updated)
U.S. STOCKS ON THE MOVE-Starbucks, Crocs, Accenture
U.S. STOCKS ON THE MOVE-Crocs, First Solar, Qualcomm
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Sickle cell drug developers rise after Pfizer withdraws its treatment
Brief: Fulcrum Therapeutics Says It Plans To Reduce Workforce
Brief: TCG Crossover GP II Reports 9.4% Passive Stake In Fulcrum Therapeutics As Of Sept 12 - SEC Filing